MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (627)	2/2/1998 5:13:00 PM
From: David Cathcart	Read Replies (1) of 1826

Richard, In my conversation with Lori last week, she said that quite a few brokers are following the company. However, only Taglich Brothers and Joseph vonMeister have written reports on the company recently. JVM, until recently, worked for a relatively small firm. Thus Taglich Brothers is likely the firm listed as "strong buy" on the site you referenced. MGI Pharma is not an easy story to understand. Much hinges on the unknown potential of Salagen in the Sjogren's market and the unknown, though potentially huge, potential of MGI-114 in the cancer market. So, I think it is appropriate that few high profile brokers are following the company now. Let's see what happens as the story unfolds. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next